|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The C677T genotype of MTHFR is associated with CVD in ESRD and may be a more meaningful marker than tHcy for abnormal homocysteine metabolism in ESRD.
|
11532106 |
2001 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The C677T mutation of the MTHFR gene may be an independent risk factor that predicts the development of carotid atherosclerosis in ESRD patients.
|
11287760 |
2001 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To evaluate the respective roles of residual glomerular filtration (by measuring a specific protein marker, cystatin C), genetic polymorphisms and nutritional status in tHcy blood levels in end-stage renal disease patients (ESRD) under hemodialysis and supplemented with folate, we measured tHcy, folate, vitamin B12 (B12), creatinine, cystatin C, albumin and C-reactive protein and determined the polymorphism of methylenetetrahydrofolate reductase (MTHFR) (C677T and A1289C) and of methionine synthase (MS) (A2756G) in 114 ESRD patients before hemodialysis and 76 control subjects.
|
11592445 |
2001 |
|
rs1799983
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition, a mutation, Glu298Asp, in exon 7 of NOS3 and a 27 bp variable number tandem repeat (VNTR) marker in intron 4 of NOS3 were evaluated in the sibling pairs and in an additional 92 unrelated African-Americans with type 2 diabetes mellitus-associated ESRD (singletons).
|
11071967 |
2000 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The genotype of the MTHFR gene in 106 patients with ESRD was homozygous C677T mutation (VV) in 17 patients (16.1%) and heterozygous (AV) in 63 patients (58.4%); 26 patients (24.5%) did not carry this mutation (AA).
|
10430972 |
1999 |
|
rs699
|
|
|
0.090 |
GeneticVariation |
BEFREE |
We conclude that heterozygous substitutions at the AGT M235T and REN A/G(I8-83) loci correlate significantly with ESRD in a north Indian population.
|
25660845 |
2015 |
|
rs699
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Furthermore, there was no a markedly positive association between AGT M235T gene polymorphism and ESRD susceptibility in overall populations, Asians and Africans.
|
23065231 |
2013 |
|
rs699
|
|
|
0.090 |
GeneticVariation |
BEFREE |
This study was designed to evaluate the angiotensin-converting enzyme insertion/deletion (ACE-I/D), angiotensinogen (AGT) M235T, and angiotensin II receptor type 1 (ATR1) A1166C and type 2 (ATR2) C3123A gene polymorphisms as risk factors for progression to ESRD in patients with VUR.Methods.
|
19288324 |
2009 |
|
rs699
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Two hundred and forty-six end-stage renal disease (ESRD) patients on peritoneal dialysis and 183 control subjects, all of Chinese origin, were genotyped for the ACE insertion/deletion (I/D) and the AGT M235T gene polymorphisms.
|
12675870 |
2003 |
|
rs699
|
|
|
0.090 |
GeneticVariation |
BEFREE |
We studied retrospectively the role of angiotensinogen (AGT) M235T, angiotensin converting enzyme (ACE) insertion/deletion (I/D), angiotensin II type 1 receptor (AT1R) A1166C, aldosterone syntase (CYP11B2) -344C/T and intron 2 W/C polymorphisms in conjunction with clinical and biochemical covariables on the rate of progression of renal insufficiency in a group of patients with ESRD of various etiologies.
|
12832734 |
2003 |
|
rs699
|
|
|
0.090 |
GeneticVariation |
BEFREE |
There were no differences in the prevalence of hypertension and the ages at the ESRD in relation to the AGT M235T and ATR A1166C polymorphisms.
|
12950120 |
2003 |
|
rs699
|
|
|
0.090 |
GeneticVariation |
BEFREE |
There was no association between age at onset of ESRD and either M235T or A1166C polymorphism.
|
11136175 |
2001 |
|
rs699
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: risk of chronic renal failure. End-Stage Renal Disease Study Group.
|
10916074 |
2000 |
|
rs699
|
|
|
0.090 |
GeneticVariation |
BEFREE |
There was no interaction between age of onset of ESRF and either the angiotensinogen M235T allele or angiotensin 1 receptor A1166C polymorphism.
|
9291178 |
1997 |
|
rs1267969615
|
|
|
0.060 |
GeneticVariation |
BEFREE |
This study was designed to evaluate the angiotensin-converting enzyme insertion/deletion (ACE-I/D), angiotensinogen (AGT) M235T, and angiotensin II receptor type 1 (ATR1) A1166C and type 2 (ATR2) C3123A gene polymorphisms as risk factors for progression to ESRD in patients with VUR.Methods.
|
19288324 |
2009 |
|
rs1267969615
|
|
|
0.060 |
GeneticVariation |
BEFREE |
We studied retrospectively the role of angiotensinogen (AGT) M235T, angiotensin converting enzyme (ACE) insertion/deletion (I/D), angiotensin II type 1 receptor (AT1R) A1166C, aldosterone syntase (CYP11B2) -344C/T and intron 2 W/C polymorphisms in conjunction with clinical and biochemical covariables on the rate of progression of renal insufficiency in a group of patients with ESRD of various etiologies.
|
12832734 |
2003 |
|
rs1267969615
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Two hundred and forty-six end-stage renal disease (ESRD) patients on peritoneal dialysis and 183 control subjects, all of Chinese origin, were genotyped for the ACE insertion/deletion (I/D) and the AGT M235T gene polymorphisms.
|
12675870 |
2003 |
|
rs1267969615
|
|
|
0.060 |
GeneticVariation |
BEFREE |
There was no association between age at onset of ESRD and either M235T or A1166C polymorphism.
|
11136175 |
2001 |
|
rs1267969615
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: risk of chronic renal failure. End-Stage Renal Disease Study Group.
|
10916074 |
2000 |
|
rs1267969615
|
|
|
0.060 |
GeneticVariation |
BEFREE |
There was no interaction between age of onset of ESRF and either the angiotensinogen M235T allele or angiotensin 1 receptor A1166C polymorphism.
|
9291178 |
1997 |
|
rs1801282
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We detected significant interactions between SNPs including PPAR-γ Pro12Ala, C161T, and GPX1 regarding the risk of ESRD.Conclusion.
|
26881045 |
2016 |
|
rs1805192
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We detected significant interactions between SNPs including PPAR-γ Pro12Ala, C161T, and GPX1 regarding the risk of ESRD.Conclusion.
|
26881045 |
2016 |
|
rs1801282
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Cox's proportional hazard regression showed that both Pro12Ala and C161T polymorphisms were significant predictors of mortality in ESRD patients with DM (Pro12Ala: GG versus other genotypes, hazard ratio [HR] <0.01; P < 0.001; for C161T, CC versus TT genotypes, HR 2.86; P < 0.001; CT versus TT genotypes, HR 1.93; P < 0.001).
|
25784779 |
2015 |
|
rs1805192
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Cox's proportional hazard regression showed that both Pro12Ala and C161T polymorphisms were significant predictors of mortality in ESRD patients with DM (Pro12Ala: GG versus other genotypes, hazard ratio [HR] <0.01; P < 0.001; for C161T, CC versus TT genotypes, HR 2.86; P < 0.001; CT versus TT genotypes, HR 1.93; P < 0.001).
|
25784779 |
2015 |
|
rs1801282
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Future research should focus on the effect of Pro12Ala polymorphism on ESRD and gathering data of Africans.
|
22619290 |
2012 |